Phase III Clinical Study of ME3208 in Patients with Steroid-Dependent/Resistant Chronic Graft Versus Host Disease

Status: Recruiting

Phase of Trial: Phase III

Latest Information Update: 25 Oct 2024

Price :

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

01 Oct 2024 Results assessing efficacy and safety of belumosudil 200 mg once daily as a second or subsequent line of therapy in Japanese patients with steroid-dependent/steroid-resistant cGVHD were published in the American Journal of Hematology.
17 Jun 2024 According to a Meiji Seika Pharma media release, results from this trial were presented on 14 June at the Congress of European Hematology Association (EHA2024) held in Madrid.
17 Jun 2024 Results presented in a Meiji Seika Pharma media release.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com